Published in Cancer Res on August 01, 1999
Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev (2005) 2.56
Biology and management of pancreatic cancer. Gut (2007) 2.53
The mTOR signalling pathway in human cancer. Int J Mol Sci (2012) 2.38
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell (2014) 2.09
Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol (2014) 1.95
MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem (2011) 1.88
The targets of curcumin. Curr Drug Targets (2011) 1.76
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol (2009) 1.70
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol (2009) 1.65
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood (2006) 1.58
FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse. Proc Natl Acad Sci U S A (2001) 1.48
mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer (2008) 1.37
Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr Protein Pept Sci (2011) 1.37
The complexes of mammalian target of rapamycin. Curr Protein Pept Sci (2010) 1.33
Updates of mTOR inhibitors. Anticancer Agents Med Chem (2010) 1.27
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer (2010) 1.21
Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol (2002) 1.18
MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. BMC Cancer (2012) 1.13
mTOR signaling in cancer cell motility and tumor metastasis. Crit Rev Eukaryot Gene Expr (2010) 1.13
OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death Dis (2011) 1.06
GDF15 triggers homeostatic proliferation of acid-secreting collecting duct cells. J Am Soc Nephrol (2008) 1.05
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica (2012) 1.05
The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. J Exp Clin Cancer Res (2009) 1.05
Rapamycin partially mimics the anticancer effects of calorie restriction in a murine model of pancreatic cancer. Cancer Prev Res (Phila) (2011) 1.01
PI3Kinase signaling in glioblastoma. J Neurooncol (2010) 1.01
Restoration of functional gap junctions through internal ribosome entry site-dependent synthesis of endogenous connexins in density-inhibited cancer cells. Mol Cell Biol (2005) 1.00
Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status. Med Sci Monit Basic Res (2014) 0.98
Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells. BMC Cancer (2010) 0.94
Mechanisms of nordihydroguaiaretic acid-induced growth inhibition and apoptosis in human cancer cells. Br J Cancer (2002) 0.90
Exploiting novel molecular targets in gastrointestinal cancers. World J Gastroenterol (2007) 0.88
SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1. Mol Endocrinol (2014) 0.86
Combination of autophagy inducer rapamycin and oncolytic adenovirus improves antitumor effect in cancer cells. Virol J (2013) 0.86
New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma. Cancer (2011) 0.85
Chemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics. Int J Mol Sci (2013) 0.84
Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer. Neoplasia (2012) 0.83
The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut Liver (2010) 0.82
P70S6K and Elf4E dual inhibition is essential to control bladder tumor growth and progression in orthotopic mouse non-muscle invasive bladder tumor model. J Korean Med Sci (2015) 0.79
Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts. BMC Cancer (2016) 0.79
A genome-wide siRNA screen in mammalian cells for regulators of S6 phosphorylation. PLoS One (2015) 0.78
A genome-wide RNAi screen for polypeptides that alter rpS6 phosphorylation. Methods Mol Biol (2012) 0.78
U12, a UDCA derivative, acts as an anti-hepatoma drug lead and inhibits the mTOR/S6K1 and cyclin/CDK complex pathways. PLoS One (2014) 0.77
Translational Upregulation of an Individual p21Cip1 Transcript Variant by GCN2 Regulates Cell Proliferation and Survival under Nutrient Stress. PLoS Genet (2015) 0.76
A combined, rational approach towards inhibition of the MEK-ERK and mTOR pathways in pancreatic ductal adenocarcinoma: promise or deja vu? Cancer Biol Ther (2009) 0.76
Cytoplasmic TRAF4 contributes to the activation of p70s6k signaling pathway in breast cancer. Oncotarget (2015) 0.75
Interferon-α enhances the susceptibility of renal cell carcinoma to rapamycin by suppressing mTOR activity. Exp Ther Med (2014) 0.75
SiRNA Targeting mTOR Effectively Prevents the Proliferation and Migration of Human Lens Epithelial Cells. PLoS One (2016) 0.75
AXIN1 protects against testicular germ cell tumors via the PI3K/AKT/mTOR signaling pathway. Oncol Lett (2017) 0.75
Connections between single-cell biomechanics and human disease states: gastrointestinal cancer and malaria. Acta Biomater (2005) 4.22
Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology (1998) 3.95
A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. EMBO J (1993) 3.74
Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer (2007) 3.49
Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest (1998) 2.90
Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology (1993) 2.83
Distinct combinations of NF-kappa B subunits determine the specificity of transcriptional activation. Proc Natl Acad Sci U S A (1992) 2.72
Relation of smoking and alcohol and coffee consumption to active Helicobacter pylori infection: cross sectional study. BMJ (1997) 2.65
p300 acts as a transcriptional coactivator for mammalian Notch-1. Mol Cell Biol (2001) 2.64
Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene (1997) 2.58
Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res (2001) 2.29
NF-kappaB/Rel activation in cerulein pancreatitis. Gastroenterology (1999) 2.21
Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. Arch Surg (1999) 2.20
Evaluating pain and the quality of life in chronic pancreatitis. Int J Pancreatol (1997) 2.16
Probe-based confocal laser endomicroscopy compared with standard four-quadrant biopsy for evaluation of neoplasia in Barrett's esophagus. Endoscopy (2010) 2.11
A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Genes Dev (2001) 2.05
[S3-Guidelines Conference "Colorectal Carcinoma" 2004]. Z Gastroenterol (2004) 2.03
Prospective evaluation of brush cytology of biliary strictures during endoscopic retrograde cholangiopancreatography. Endoscopy (1999) 2.02
[Prospective Epidemiologic Study of Epigastric Discomfort (PRESTO). Ground work and preliminary results]. Dtsch Med Wochenschr (1999) 2.01
Dimerization of NF-KB2 with RelA(p65) regulates DNA binding, transcriptional activation, and inhibition by an I kappa B-alpha (MAD-3). Mol Cell Biol (1993) 2.00
Parental smoking and infection with Helicobacter pylori among preschool children in southern Germany. Epidemiology (1998) 1.98
NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol (1998) 1.96
Helicobacter pylori among preschool children and their parents: evidence of parent-child transmission. J Infect Dis (1999) 1.96
Metabolic and weight-loss effects of a long-term dietary intervention in obese patients. Am J Clin Nutr (1999) 1.92
Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res (2000) 1.90
Intra-acinar cell activation of trypsinogen during caerulein-induced pancreatitis in rats. Am J Physiol (1998) 1.89
Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut (2000) 1.86
[Update S3-guideline "colorectal cancer" 2008]. Z Gastroenterol (2008) 1.81
Is stenting necessary after balloon dilation of post-transplantation biliary strictures? Results of a prospective comparative study. Endoscopy (2008) 1.76
The effect of sedation on the quality of upper gastrointestinal endoscopy: an investigator-blinded, randomized study comparing propofol with midazolam. Endoscopy (2007) 1.76
Molecular cloning and characterization of the human protein kinase D2. A novel member of the protein kinase D family of serine threonine kinases. J Biol Chem (2000) 1.76
Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology (2001) 1.75
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol (2011) 1.74
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol (2005) 1.71
Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer (1995) 1.67
Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev (1999) 1.64
Malignant transformation of duct-like cells originating from acini in transforming growth factor transgenic mice. Gastroenterology (1998) 1.60
Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Oncogene (1999) 1.60
Inflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotion. Proc Natl Acad Sci U S A (2009) 1.60
Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology (2000) 1.56
Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. Obes Res (2000) 1.56
A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. Cancer Res (2000) 1.55
Cystic tumours of the pancreas: diagnostic accuracy, pathologic observations and surgical consequences. Langenbecks Arch Surg (1998) 1.55
The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. Gut (1997) 1.54
[S3-Guidelines "Exocrine pancreatic cancer" 2007]. Z Gastroenterol (2007) 1.52
Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun (1998) 1.52
Transcriptional regulation of NF-kappa B2: evidence for kappa B-mediated positive and negative autoregulation. Mol Cell Biol (1994) 1.51
A pancreatic cancer-specific expression profile. Oncogene (1996) 1.50
Characteristic distribution pattern of Helicobacter pylori in dental plaque and saliva detected with nested PCR. J Med Microbiol (2000) 1.50
Genetic alterations in chronic pancreatitis: evidence for early occurrence of p53 but not K-ras mutations. Br J Surg (1998) 1.46
Helicobacter pylori and abdominal symptoms: a population-based study among preschool children in southern Germany. Pediatrics (1998) 1.46
Course and spontaneous regression of acute pancreatitis in the rat. Virchows Arch A Pathol Anat Histol (1979) 1.45
Identification of mediators stimulating proliferation and matrix synthesis of rat pancreatic stellate cells. Am J Physiol Cell Physiol (2001) 1.45
Proinflammatory cytokines increase glial fibrillary acidic protein expression in enteric glia. Gut (2004) 1.43
Hormone-induced pancreatitis. Eur Surg Res (1992) 1.42
Phenylalanine kinetics in healthy volunteers and liver cirrhotics: implications for the phenylalanine breath test. Am J Physiol Endocrinol Metab (2002) 1.41
Platelet-derived growth factors stimulate proliferation and extracellular matrix synthesis of pancreatic stellate cells: implications in pathogenesis of pancreas fibrosis. Lab Invest (2000) 1.40
Sympathetic modulation of lipolysis in subcutaneous adipose tissue: effects of gender and energy restriction. J Lab Clin Med (1999) 1.40
Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer (2000) 1.39
Cross talk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene (2010) 1.38
Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res (2001) 1.36
Specific NF-kappa B subunits act in concert with Tat to stimulate human immunodeficiency virus type 1 transcription. J Virol (1992) 1.34
Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res (1997) 1.33
CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. Gut (2009) 1.31
Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol (2010) 1.27
Pathophysiologic role of oxygen free radicals in acute pancreatitis: initiating event or mediator of tissue damage? Ann Surg (2000) 1.26
Time course and cellular source of pancreatic regeneration following acute pancreatitis in the rat. Pancreas (1986) 1.26
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut (2009) 1.26
A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis. Gut (1999) 1.26
Balance of expression of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in chronic pancreatitis. Z Gastroenterol (1994) 1.25
TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer (2001) 1.24
Alteration of membrane fusion as a cause of acute pancreatitis in the rat. Dig Dis Sci (1982) 1.24
The human tumor necrosis factor (TNF) receptor-associated factor 1 gene (TRAF1) is up-regulated by cytokines of the TNF ligand family and modulates TNF-induced activation of NF-kappaB and c-Jun N-terminal kinase. J Biol Chem (1999) 1.22
S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol (2010) 1.20
Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines. Gastroenterology (2001) 1.20
Dissociation and reassembly of adherens junctions during experimental acute pancreatitis. Gastroenterology (1997) 1.19
Oxidized low-density lipoproteins bind to the scavenger receptor, CD36, of hepatic stellate cells and stimulate extracellular matrix synthesis. Hepatology (2001) 1.19
Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med (1997) 1.19
Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Cancer Res (1996) 1.19
Enhancement of transforming growth factor beta 1 expression in the rat pancreas during regeneration from caerulein-induced pancreatitis. Eur J Clin Invest (1994) 1.19
From acinar cell damage to systemic inflammatory response: current concepts in pancreatitis. Pancreatology (2001) 1.18
Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene. Cancer Res (1997) 1.17